Session Speaker

The Lilly Phenotypic Drug Discovery (PD²) Initiative: An Invitation to an Open Innovation Model in Drug Discovery.
Jay McGill
USA

Today Lilly is dedicated to the goal of becoming part of a Fully Integrated Pharmaceutical Network (FIPNet). A key part of this transformation is to expand the level of collaborative research with universities, institutes, and biotech to fuel innovative discovery. Through our Phenotypic Drug Discovery efforts, Lilly has established a panel of five phenotypic assay modules which represent therapeutic areas of long-term strategic interest such as oncology, neurological disorders, and metabolic diseases. Lilly now provides access to these assay modules to external investigators, at no cost to them, through the PD² website (pd2.lilly.com), Lilly's new collaborative initiative. Each assay module is composed of a phenotypic lead generation assay, followed by relevant biochemical and cellular follow-up assays, designed to define a compound's activity profile and early potential for further drug optimization. This presentation will present an overview of PD², the open innovation model through which Lilly works with research universities, institutes, and biotech to uncover compounds that may become future medicines and impact patients' lives.